Cognex (NASDAQ:CGNX) Announces Earnings Results

Cognex (NASDAQ:CGNX) released its quarterly earnings data on Wednesday. The scientific and technical instruments company reported $0.34 EPS for the quarter, beating analysts’ consensus estimates of $0.25 by $0.09, FiscalAI reports. The company had revenue of $268.44 million during the quarter, compared to the consensus estimate of $245.98 million. Cognex had a net margin of 11.51% and a return on equity of 9.02%. Cognex updated its Q2 2026 guidance to 0.400-0.440 EPS.

Cognex Price Performance

Shares of NASDAQ:CGNX traded up $3.43 during mid-day trading on Wednesday, reaching $62.26. 6,817,557 shares of the company were exchanged, compared to its average volume of 2,124,689. The firm has a market cap of $10.40 billion, a price-to-earnings ratio of 92.93 and a beta of 1.48. The firm’s 50-day simple moving average is $52.39 and its 200 day simple moving average is $44.95. Cognex has a 1 year low of $27.82 and a 1 year high of $63.01.

Cognex Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 12th. Investors of record on Thursday, February 26th were given a dividend of $0.085 per share. The ex-dividend date of this dividend was Thursday, February 26th. This represents a $0.34 dividend on an annualized basis and a dividend yield of 0.5%. Cognex’s dividend payout ratio (DPR) is presently 50.75%.

Insider Buying and Selling

In related news, Director Angelos Papadimitriou sold 4,150 shares of the stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $55.58, for a total transaction of $230,657.00. Following the completion of the transaction, the director owned 16,222 shares of the company’s stock, valued at approximately $901,618.76. This trade represents a 20.37% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Laura Ann Macdonald sold 14,881 shares of the stock in a transaction that occurred on Thursday, February 12th. The stock was sold at an average price of $57.16, for a total transaction of $850,597.96. Following the transaction, the vice president directly owned 2,212 shares of the company’s stock, valued at $126,437.92. The trade was a 87.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 196,083 shares of company stock valued at $11,419,321. Company insiders own 1.70% of the company’s stock.

Hedge Funds Weigh In On Cognex

A number of hedge funds have recently made changes to their positions in CGNX. Royal Bank of Canada boosted its position in shares of Cognex by 13.2% during the 1st quarter. Royal Bank of Canada now owns 200,351 shares of the scientific and technical instruments company’s stock worth $5,976,000 after purchasing an additional 23,326 shares during the period. Empowered Funds LLC purchased a new position in Cognex in the 1st quarter valued at approximately $291,000. Intech Investment Management LLC boosted its position in Cognex by 24.1% in the 1st quarter. Intech Investment Management LLC now owns 47,444 shares of the scientific and technical instruments company’s stock valued at $1,415,000 after buying an additional 9,223 shares during the period. Geneos Wealth Management Inc. boosted its position in Cognex by 402.2% in the 1st quarter. Geneos Wealth Management Inc. now owns 919 shares of the scientific and technical instruments company’s stock valued at $27,000 after buying an additional 736 shares during the period. Finally, Cetera Investment Advisers boosted its position in Cognex by 7.5% in the 2nd quarter. Cetera Investment Advisers now owns 13,208 shares of the scientific and technical instruments company’s stock valued at $419,000 after buying an additional 920 shares during the period. Hedge funds and other institutional investors own 88.12% of the company’s stock.

Wall Street Analyst Weigh In

CGNX has been the subject of several analyst reports. Robert W. Baird set a $55.00 price target on shares of Cognex in a research note on Tuesday, February 17th. Needham & Company LLC increased their price target on shares of Cognex from $47.00 to $67.00 and gave the company a “buy” rating in a research note on Thursday, February 12th. TD Cowen reissued a “buy” rating on shares of Cognex in a research note on Tuesday, February 17th. Barclays increased their price target on shares of Cognex from $61.00 to $64.00 and gave the company an “overweight” rating in a research note on Monday, March 16th. Finally, DA Davidson set a $55.00 price target on shares of Cognex and gave the company a “neutral” rating in a research note on Tuesday, February 17th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $59.50.

Cognex Company Profile

Cognex Corporation is a leading provider of machine vision systems, software, sensors and industrial barcode readers used to automate manufacturing, logistics and distribution processes. The company designs and develops vision-based products that help manufacturers and logistics operators inspect, identify and guide parts, assemblies and packaged goods in real time. Its solutions are applied in a broad range of industries, including automotive, electronics, semiconductor, pharmaceutical, food and beverage, and general manufacturing.

The company’s product portfolio includes stand-alone vision systems, vision sensors and deep learning-based software platforms that enable automated inspection, quality control and traceability.